KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $109.9 million.

  • Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) fell 3.85% to $106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.0 million, marking a year-over-year decrease of 3.85%. This contributed to the annual value of $109.9 million for FY2024, which is 0.87% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $109.9 million, which was up 0.87% from $108.9 million recorded in FY2023.
  • Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $109.9 million during FY2024, with a 5-year trough of $106.7 million in FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $109.2 million, with a median of $108.9 million in 2023.
  • In the last 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) dropped by 2.81% in 2020 and then climbed by 1.26% in 2022.
  • Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $106.7 million in 2020, then increased by 0.78% to $107.5 million in 2021, then climbed by 1.26% to $108.9 million in 2022, then increased by 0.04% to $108.9 million in 2023, then climbed by 0.87% to $109.9 million in 2024.